Significant Revenue and Royalty Growth
Full year GAAP income and revenue grew to $52.1M from $28.5M in 2024 (≈+82.8%). Total portfolio cash receipts reached $50.5M (+9% YoY) and royalty receipts were $34M, a 68% increase versus 2024.
Positive GAAP Net Income and Operating Cash Flow
GAAP net income of $31.7M in 2025 compared to a GAAP net loss of $13.8M in 2024, and the company achieved positive cash flow from operations during the year.
Portfolio Expansion and Diversification
Added 22 assets to the portfolio in 2025 plus acquisition of 2 platform technologies. Portfolio expanded from ~60 assets in 2023 to over 120 today (≈+100%), with seven commercially available programs and 14 programs in registrational stage.
Successful Dealmaking and Low Upfront Capital Deployment
Executed 2025 transactions that added 22 assets with only $25M upfront cash; strategic revenue share with Takeda added economic interest across 9 programs and up to $853M in potential milestones.
Capital Return to Shareholders
Returned $16M via opportunistic share repurchases, retiring ~648,000 shares (~>5% of outstanding) at an average price of $24.75, while maintaining share count essentially flat vs 2023 overall.
Strengthened Balance Sheet and Liquidity
Unrestricted cash and cash equivalents ended the year at approximately $83M, providing capital to continue portfolio expansion and business development.
Track Record of Recovering Investments
Prior transactions produced strong returns: Viracta/OJEMDA monetization delivered >$28M in milestones and ~$8M in royalties (>30% IRR); MIPLYFFA investment recovered upfront within ~15 months via milestones and royalties.
Debt Reduction Progress
Reduced Blue Owl loan principal from $123M to $112.5M during 2025; loan is self-amortizing and repaid solely from VABYSMO receipts, with potential full repayment by end of 2030 if trends persist.